Drugs that contain Esketamine Hydrochloride
1. Drug name - SPRAVATO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592207 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Mar, 2027
(4 years from now) | |
| US8785500 | JANSSEN PHARMS | Intranasal administration of ketamine to treat depression |
Jul, 2031
(8 years from now) | |
| US10869844 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(12 years from now) | |
| US11173134 | JANSSEN PHARMS | Methods for the treatment of depression |
Sep, 2035
(12 years from now) | |
Treatment: Treatment of treatment-resistant depression in adult in conjunction with an oral antidepressant; Treatment of depressive symptoms in adults with mdd with acute suicidal ideation or behavior by nasally administering 56mg or 84 mg of esketamine 2x weekly for 4 weeks in conjunction with an oral antidepressant; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase in conjunction with an oral antidepressent; treatment of trd in adults by nasally administering 56mg or 84mg of esketamine 2x weekly for 4 weeks during the induction phase followed by a maintenance phase of 56mg or 84 mg weekly or 1x every two weeks in conjunction with an oral antidepressant; Treatment of trd in conjunction with an oral antidepressant by nasally administering 56mg or 84mg of esketamine in a maintenance phase weekly or 1x every two weeks to adults who have been administered esketamine in a induction phase for about 4 weeks
Dosage: SPRAY;NASAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 28MG BASE | SPRAY;NASAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.